Home » Stocks » BLUE

Bluebird Bio, Inc. (BLUE)

Stock Price: $28.25 USD -0.43 (-1.50%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $28.50 +0.25 (0.89%) Mar 8, 7:57 PM
Market Cap 1.92B
Revenue (ttm) 250.73M
Net Income (ttm) -618.70M
Shares Out 62.18M
EPS (ttm) -9.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $28.25
Previous Close $28.68
Change ($) -0.43
Change (%) -1.50%
Day's Open 28.86
Day's Range 28.19 - 29.66
Day's Volume 1,037,469
52-Week Range 24.24 - 72.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 1 hour ago

New York, New York--(Newsfile Corp. - March 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) ...

Business Wire - 3 hours ago

NEW YORK--(BUSINESS WIRE)---- $BLUE--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on be...

Newsfile Corp - 4 hours ago

New York, New York--(Newsfile Corp. - March 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between...

Newsfile Corp - 8 hours ago

New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

Newsfile Corp - 1 day ago

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE...

Newsfile Corp - 2 days ago

New York, New York--(Newsfile Corp. - March 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

GlobeNewsWire - 2 days ago

NEW YORK, March 06, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motio...

Newsfile Corp - 3 days ago

New York, New York--(Newsfile Corp. - March 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) ...

Newsfile Corp - 3 days ago

Philadelphia, Pennsylvania--(Newsfile Corp. - March 5, 2021) -  Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. ("bluebird" or the "Company") on b...

Newsfile Corp - 3 days ago

New York, New York--(Newsfile Corp. - March 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

PRNewsWire - 4 days ago

LOS ANGELES, March 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against bluebird bio, Inc. ("blueb...

Newsfile Corp - 5 days ago

New York, New York--(Newsfile Corp. - March 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

GlobeNewsWire - 5 days ago

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2...

GlobeNewsWire - 6 days ago

LEAD PLAINTIFF DEADLINE IS APRIL 13, 2021 LEAD PLAINTIFF DEADLINE IS APRIL 13, 2021

Newsfile Corp - 6 days ago

New York, New York--(Newsfile Corp. - March 2, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) ...

PRNewsWire - 6 days ago

NEW YORK, March 1, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 a...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - March 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

GlobeNewsWire - 1 week ago

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motio...

Business Wire - 1 week ago

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wedne...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 25, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BL...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

Other stocks mentioned: CLOV, IRTC, TSN
Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb's (NYSE: BMY) ...

Other stocks mentioned: BMY
Business Wire - 1 week ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BL...

Zacks Investment Research - 1 week ago

bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion...

Business Wire - 1 week ago

LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

Business Wire - 1 week ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BL...

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of bluebird bio, Inc. (NASDAQ: BLUE) from May 11, 20...

The Motley Fool - 1 week ago

Investors are ditching this gene therapy stock en masse, for good reason.

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 23, 2021) - WHY:  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of th...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and sh...

Newsfile Corp - 1 week ago

Los Angeles, California--(Newsfile Corp. - February 23, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against blue...

Business Wire - 1 week ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio,...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Confe...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: ...

Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of BLUE Inves...

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of bluebird bio, Inc. (NASDAQ:BLUE) between May 11, ...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 19, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: B...

Business Wire - 2 weeks ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $BLUE #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) I...

Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $BLUE #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed in the United States ...

PRNewsWire - 2 weeks ago

PHILADELPHIA, Feb. 19, 2021 /PRNewswire/ -- Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. ("bluebird" or the "Company") on behalf of investors w...

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain o...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ...

Newsfile Corp - 2 weeks ago

Los Angeles, California--(Newsfile Corp. - February 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against blueb...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 18, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BL...

About BLUE

bluebird bio, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2013
CEO
Nick Leschly
Employees
1,201
Stock Exchange
NASDAQ
Ticker Symbol
BLUE
Full Company Profile

Financial Performance

In 2020, Bluebird Bio's revenue was $250.73 million, an increase of 461.25% compared to the previous year's $44.67 million. Losses were -$618.70 million, -21.65% less than in 2019.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for Bluebird Bio stock is "Buy." The 12-month stock price forecast is 46.53, which is an increase of 64.71% from the latest price.

Price Target
$46.53
(64.71% upside)
Analyst Consensus: Buy